Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2019

01-02-2019 | Original Article

Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)

Authors: Cem Mirili, Isa Burak Guney, Semra Paydas, Gulsah Seydaoglu, Tuba Korkmaz Kapukaya, Ali Ogul, Serkan Gokcay, Mahmut Buyuksimsek, Abdullah Evren Yetisir, Bilgin Karaalioglu, Mert Tohumcuoglu

Published in: International Journal of Clinical Oncology | Issue 2/2019

Login to get access

Abstract

Purpose

The aim of this study is to detect the prognostic significance of neutrophil/lymphocyte ratio (NLR) in SCLC and to evaluate the relation with 18F-FDG PET–CT metabolic parameters (PET–CT MPs).

Methods

Demographic parameters, laboratory values including NLR and other clinical variables were analyzed in 112 patients with small cell lung cancer (SCLC) and 54 of these patients had results of metabolic parameters detected with 18 FDG PET–CT [including SUVmax, SUVmean, metabolic tumor volume (MTV), whole body MTV (WBMTV), TLG (total lesion glycolysis), whole body TLG (WBTLG)] were evaluated for survival analyses.

Results

Mean and median overall survival (OS) and progression-free survival (PFS) were found to be significantly longer in cases with NLR < 4 compared with NLR > 4 in totally. Also stage, performance status, response to first-line therapy, LDH, and lymphocyte count were found to be prognostic for OS and PFS. MTV, WBMTV and WBTLG were found to be prognostic for both OS and PFS, while SUVmax found to be significant for OS. Patients with NLR ≥ 4, MTV ≥ 60.1, WBMTV ≥ 120 and WBTLG ≥ 1000 points had lower OS and PFS. A moderate positive correlation was found between NLR and SUVmean (r: 0.36), SUVmax (r: 0.34), TLG (r: 0.39), MTV (r: 0.51), WBMTV (r: 0.40), and WBTLG (r: 0.46).

Conclusion

There is relationship between PET–CT metabolic parameters and NLR in SCLC. Highest correlation was found with NLR and MTV, WBMTV, and WBTLG, and evaluation of NLR together with these parameters predicts survival times and tumor biology more clearly in SCLC.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E365–E368CrossRef
2.
Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544PubMedCrossRef
3.
Stupp R, Monnerat C, Turrisi AT et al (2004) Small cell lung cancer: state of the art and future perspectives. Lung cancer 45(1):105–117PubMedCrossRef
4.
Yip D, Harper PG (2000) Predictive and prognostic factors in small cell lung cancer: current status. Lung cancer 28(3):173–185PubMedCrossRef
5.
Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer 37(3):271–276PubMedCrossRef
6.
Edge S, Byrd DR, Compton CC et al (2010) American Joint Committee on Cancer (AJCC). In: Cancer staging handbook, 7th edn. Springer, New York, pp 299–323
7.
Kalemkerian GP, Schneider BJ (2017) Advances in small cell lung cancer. Hematol Oncol Clin North Am 31(1):143–156PubMedCrossRef
8.
Jett JR, Schild SE, Kesler KA et all (2013) Treatment of small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5):e400S–e419SPubMedCrossRef
9.
van Loon J, De Ruysscher D, Wanders R et al (2010) Selective nodal irradiation on basis of 18FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 77(2):329–336PubMedCrossRef
10.
Sasaki R, Komaki R, Macapinlac H et al (2005) [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non–small-cell lung cancer. J Clin Oncol 23(6):1136–1143PubMedCrossRef
11.
Davies A, Tan C, Paschalides C et al (2007) FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 55(1):75–78PubMedCrossRef
12.
Guo H, Zhu H, Xi Y et all (2007) Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 48(8):1251–1258PubMedCrossRef
13.
Lund AA, Vilstrup MH, Jochumsen KM et al (2017) Prognostic Evaluation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in endometrial cancer: a retrospective study. Int J Gynecol Cancer 27(8):1675–1684PubMedCrossRef
14.
Xie P, Yue JB, Fu Z et al (2009) Prognostic value of 18F-FDG PET-CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 21(5):1078–1082PubMedCrossRef
15.
Zhang H, Wroblewski K, Liao S et al (2013) Prognostic value of metabolic tumor burden from 18F-FDG PET in surgical patients with non–small-cell lung cancer. Acad Radiol 20(1):32–40PubMedCrossRef
16.
Tamandl D, Ta J, Schmid R et al (2016) Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer. Eur J Radiol 85(3):540–545PubMedCrossRef
17.
Satoh Y, Onishi H, Nambu A et al (2014) Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Radiology 270(1):275–281PubMedCrossRef
18.
Kim MH, Lee JS, Mok JH et al (2014) Metabolic burden measured by 18f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer. Cancer Res Treat 46(2):165–171PubMedCentralPubMedCrossRef
19.
Salavati A, Duan F, Snyder BS et al (2017) Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 44(12):1969–1983PubMedCentralPubMedCrossRef
20.
21.
Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436–444CrossRefPubMed
22.
Boissier R, Campagna J, Branger N et al (2017) The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: a review. Urol Oncol 35(4):135–141PubMedCrossRef
23.
Park SB, Choi JY, Moon SH et al (2014) Prognostic value of volumetric metabolic parameters measured by [18 F] Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14:2PubMedCentralPubMedCrossRef
24.
Kwon SH, Hyun SH, Yoon JK et al (2016) The highest metabolic activity on FDG PET is associated with overall survival in limited-stage small-cell lung cancer. Medicine 95(5):e2772PubMedCentralPubMedCrossRef
25.
Käsmann L, Bolm L, Schild SE et al (2017) Neutrophil-to-lymphocyte ratio predicts outcome in limited disease small-cell lung cancer. Lung 195(2):217–224PubMedCrossRef
26.
Wang X, Teng F, Kong L et al (2016) Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther 9:5761–5770PubMedCentralPubMedCrossRef
27.
28.
Kang MH, Go SI, Song HN et al (2014) The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer 111(3):452–460PubMedCentralPubMedCrossRef
29.
Suzuki R, Lin SH, Wei X et al (2018) Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol 126(3):499–505PubMedPubMedCentralCrossRef
30.
31.
Powell DR, Huttenlocher A (2016) Neutrophils in the tumor microenvironment. Trends Immunol 37(1):41–52PubMedCrossRef
32.
Zhao W, Wang P, Jia H et al (2017) Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care? BMC Cancer 17(1):514PubMedCentralPubMedCrossRef
33.
Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33(5):949–955PubMedCrossRef
34.
Zhou SL, Zhou ZJ, Hu ZQ et al (2016) Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology 150(7):1646–1658PubMedCrossRef
35.
Shen M, Hu P, Donskov F et al (2014) Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PloS One 9(6):e98259PubMedCentralPubMedCrossRef
36.
Gumus F, Solak I, Eryilmaz MA (2018) The effects of smoking on neutrophil/lymphocyte, platelet//lymphocyte ratios. Bratisl Lek Listy 119(2):116–119PubMed
37.
Sheikhbahaei S, Mena E, Pattanayak P et al (2017) Molecular imaging and precision medicine: PET/computed tomography and therapy response assessment in oncology. PET Clin 12:105–118PubMedCrossRef
38.
Lee YJ, Cho A, Cho BC et al (2009) High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 15(7):2426–2432PubMedCrossRef
39.
Zhu D, Ma T, Niu Z et al (2011) Prognostic significance of metabolic parameters measured by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 73(3):332–337PubMedCrossRef
40.
Oh JR, Seo JH, Chong A et al (2012) Whole-body metabolic tumour volume of 18F-FDG PET-CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging 39(6):925–935PubMedCrossRef
41.
Daisne JF, Duprez T, Weynand B et al (2004) Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233(1):93–100PubMedCrossRef
42.
Biehl KJ, Kong FM, Dehdashti F et al (2006) 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 47(11):1808–1812PubMed
43.
Kubota R, Yamada S, Kubota K et al (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33(11):1972–1980PubMed
44.
Chen HH, Chiu NT, Su WC et al (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET-CT in non-small cell lung cancer. Radiology 264(2):559–566PubMedCrossRef
45.
Sürücü E, Demir Y, Şengöz T (2015) The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer. Ann Nucl Med 29(10):906–910PubMedCrossRef
46.
Jeong E, Hyun SH, Moon SH et al (2017) Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection. Medicine (Baltimore) 96(5):e5935CrossRef
47.
Kwilas AR, Donahue RN, Tsang KY et al (2015) Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron 2(1):e677PubMedCentralPubMed
48.
Metadata
Title
Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC)
Authors
Cem Mirili
Isa Burak Guney
Semra Paydas
Gulsah Seydaoglu
Tuba Korkmaz Kapukaya
Ali Ogul
Serkan Gokcay
Mahmut Buyuksimsek
Abdullah Evren Yetisir
Bilgin Karaalioglu
Mert Tohumcuoglu
Publication date
01-02-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 2/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1338-8

Other articles of this Issue 2/2019

International Journal of Clinical Oncology 2/2019 Go to the issue

Original Article

Effect of combination of pre- and postoperative pulmonary rehabilitation on onset of postoperative pneumonia: a retrospective cohort study based on data from the diagnosis procedure combination database in Japan

Original Article

Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer

Original Article

Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study

Review Article

Clinical target sequencing for precision medicine of breast cancer

Original Article

Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City

Invited Review Article

Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits